fda warning letter compounding semaglutide news issues 30 letters to online GLP-1 compounders US FDA sends 25 letters

This has led to conceptualizing obesity as a chronic disease requiring ongoing management rather than a condition amenable to short-term cure

Review Methodology We conducted a narrative review to gather and summarize FDA-approved and investigational therapies in the medical management of obesity

A 2026 scoping review in Obesity Reviews found that caloric intake fell 24%-39% across 12 telehealth GLP-1 trials, yet only 3 of the 12 studies included a registered dietitian, which left a visible care gap around practical nutrition support

Approximately 14 states cover GLP-1 medications for weight loss as of 2025, typically with extensive prior authorization requirements

Across major clinical trials (LEADER, REWIND, SUSTAIN, SURPASS), no increase in MTC incidence has been observed, and human C-cells express very low levels of GLP-1 receptors

HRTS, the first to launch, has holdings in 30 to 40 companies